Intrinsic Edge Capital Management LLC Decreases Stock Holdings in Vericel Co. (NASDAQ:VCEL)

Intrinsic Edge Capital Management LLC lessened its stake in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 10.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 97,398 shares of the biotechnology company's stock after selling 11,946 shares during the period. Intrinsic Edge Capital Management LLC owned 0.20% of Vericel worth $5,348,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the company. Arcadia Investment Management Corp MI purchased a new position in shares of Vericel during the fourth quarter worth approximately $48,000. Smartleaf Asset Management LLC boosted its position in Vericel by 511.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock valued at $70,000 after purchasing an additional 1,058 shares in the last quarter. Meeder Asset Management Inc. grew its stake in Vericel by 8.4% in the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company's stock valued at $129,000 after purchasing an additional 183 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Vericel by 826.6% during the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock valued at $138,000 after buying an additional 2,240 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Vericel by 82.5% in the 4th quarter. KBC Group NV now owns 2,707 shares of the biotechnology company's stock worth $149,000 after buying an additional 1,224 shares during the last quarter.

Insider Buying and Selling

In other news, CEO Dominick Colangelo sold 24,850 shares of the stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $41.89, for a total value of $1,040,966.50. Following the transaction, the chief executive officer now owns 260,354 shares in the company, valued at approximately $10,906,229.06. This represents a 8.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the transaction, the director now owns 26,595 shares in the company, valued at $1,662,187.50. This represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 55,034 shares of company stock worth $2,482,291. Company insiders own 5.20% of the company's stock.

Vericel Price Performance

Shares of VCEL stock traded up $0.16 on Thursday, hitting $38.18. The stock had a trading volume of 165,438 shares, compared to its average volume of 395,101. The company's 50 day moving average price is $44.80 and its 200-day moving average price is $51.23. Vericel Co. has a 1 year low of $37.39 and a 1 year high of $63.00. The firm has a market capitalization of $1.91 billion, a P/E ratio of 635.11 and a beta of 1.61.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on VCEL shares. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Stephens reissued an "overweight" rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial lowered their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research note on Friday, April 11th. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. Finally, Canaccord Genuity Group raised their target price on Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $60.86.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.